Back grey_arrow_rt.gif
 
 
Presidio Pharmaceuticals, Inc.
to Present at the Canaccord Adams' Hepatitis C Conference
 
 
  from Jules: Presidio is developing NS5A inhibitor HCV drug and presenting data at EASL in Vienna April 14.
 
SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that Dr. Omar K. Haffar, Founder, President and Chief Executive Officer, will present an update on Presidio?s drug development activities at the Canaccord Adams Hepatitis C Conference on Thursday, April 1, 2010 at 2:30PM in the Tribeca Room at the Peninsula Hotel in New York City.
 
About Presidio
 
Presidio Pharmaceuticals, Inc. is a San Francisco-based specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics for novel and validated targets. For more information, please visit our website at: www.presidiopharma.com.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org